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Abstract
Background: Antibodies targeting blood stage antigens are important in protection against malaria, but the key targets and
mechanisms of immunity are not well understood. Merozoite surface protein 1 (MSP1) is an abundant and essential protein.
The C-terminal 19 kDa region (MSP1-19) is regarded as a promising vaccine candidate and may also be an important target
of immunity.
Methodology/Findings: Growth inhibitory antibodies against asexual-stage parasites and IgG to recombinant MSP1-19
were measured in plasma samples from a longitudinal cohort of 206 children in Papua New Guinea. Differential inhibition by
samples of mutant P. falciparum lines that expressed either the P. falciparum or P. chabaudi form of MSP1-19 were used to
quantify MSP1-19 specific growth-inhibitory antibodies. The great majority of children had detectable IgG to MSP1-19, and
high levels of IgG were significantly associated with a reduced risk of symptomatic P. falciparum malaria during the 6-month
follow-up period. However, there was little evidence of PfMSP1-19 specific growth inhibition by plasma samples from
children. Similar results were found when testing non-dialysed or dialysed plasma, or purified antibodies, or when
measuring growth inhibition in flow cytometry or microscopy-based assays. Rabbit antisera generated by immunization
with recombinant MSP1-19 demonstrated strong MSP1-19 specific growth-inhibitory activity, which appeared to be due to
much higher antibody levels than human samples; antibody avidity was similar between rabbit antisera and human plasma.
Conclusions/Significance: These data suggest that MSP1-19 is not a major target of growth inhibitory antibodies and that
the protective effects of antibodies to MSP1-19 are not due to growth inhibitory activity, but may instead be mediated by
other mechanisms. Alternatively, antibodies to MSP1-19 may act as a marker of protective immunity.
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Introduction
Between 300–500 million cases of clinical malaria occur each
year resulting in approximately 1 million deaths, mostly in
children under 5 years of age in sub Saharan Africa [1–3]. The
major causative agent of malaria mortality is Plasmodium falciparum.
Although the disease burden of P. falciparum is considered to fall
mainly in Africa, around 25% is thought to occur in Asia [4].
Malaria disease occurs during blood-stage infection when
merozoites invade human red blood cells (RBCs) and replicate
inside them. Invasion of RBCs is a complex process involving the
interaction of proteins present on the surface and within apical
organelles of the merozoite with receptors on the RBC surface
(reviewed in Gaur et al. 2004 [5]). In malaria-endemic areas
effective immunity against malaria develops after repeated
exposure that limits blood-stage parasitemia and prevents
symptomatic illness and severe complications [6]. Antibodies to
merozoite proteins appear to be an important component of
acquired immunity in humans and high levels of IgG to a number
of surface proteins and invasion ligands have been associated with
protection from malaria [7–22]. Antibodies to merozoite proteins
are thought to act by direct inhibition of invasion, and through
antibody-dependent cell-mediated immune mechanisms [23,24].
However, antibody effector mechanisms and the specific targets of
functional antibodies are poorly understood.
Merozoite surface protein 1 (MSP1), is a ,200 kDa GPI
anchored merozoite surface protein consisting of 17 blocks of
conserved and variable regions [25,26]. MSP1 is abundant on the
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unsuccessful, suggesting that MSP1 is essential for parasite
invasion and/or growth [27,28]. MSP1 is proteolytically processed
into 83-, 30-, 38-kDa, and C-terminal 42-kDa (MSP1-42)
fragments just before egress from the schizont. These are shed,
leaving only the C-terminal fragment that runs at 19 kDa on a
non-reducing gel (termed MSP1-19) on the parasite membrane
post invasion [29–35]. The function of MSP1 remains unclear, but
MSP1-19 has been reported to bind the RBC protein Band 3 [36],
and recent studies suggest MSP1-42 interacts with heparin-like
molecules on the RBC [37].
A number of studies have shown that high levels of MSP1-19
IgG antibodies measured by ELISA are associated with protection
from P. falciparum malaria [20,38–43]. Affinity purified MSP1-19
specific human antibodies to whole MSP1-19 and domain II [44]
(10–100 fold higher than initial serum concentration), but not
domain I [45], of MSP1-19 were reported to inhibit merozoite
invasion in vitro. Vaccination using recombinant MSP1-19 antigens
and passive transfer of MSP1-19 antibodies has been reported to
confer protection from malaria disease in both mouse and monkey
models of malaria [46–50].
Several mechanisms by which MSP1-19 antibodies may
mediate protection from malaria have been suggested by vaccine
studies. These include antibody binding to the 19 kDa fragment
and inhibiting protein function and merozoite invasion of
erythrocytes, disruption of secondary processing of the MSP1
precursor, agglutination of merozoites and opsonising parasites for
destruction by phagocytic cells [31,34,51–53].
Efforts to study the role and function of naturally acquired
PfMSP1-19 antibodies in protection from P. falciparum disease were
facilitated by the development of MSP1-19 transgenic parasites.
The 19 kDa fragment of P. falciparum isolate D10 (MAD-20 allele)
was replaced with the 19 kDa region of the rodent malaria P.
chabaudi (PcMEGF) [54] or with the endogenous D10 MSP1-19
sequence (PfM39) [27] to act as a wild-type control. Growth of the
PcMEGF and PfM39 lines was found to be inhibited by polyclonal
antibodies raised against the recombinant antigens, with no
evidence of significant cross inhibitory activity between antigens.
This approach provided tools to measure growth inhibitory
antibodies in vitro that are specific to MSP1-19 [54].
Several studies using these transgenic parasites have reported
that PfMSP1-19 specific antibodies are a large component of the
total in vitro growth inhibitory activity of untreated serum and
plasma from malaria-exposed individuals [54–60]. In one study
people with high levels of PfMSP1-19 specific inhibitory activity in
their plasma were less likely to be reinfected with P. falciparum after
drug treatment [55]. However, other studies using the PcMEGF,
or a similar transfectant using P. yoelii MSP1-19 (PyMEGF),
showed no association between PfMSP1-19 specific growth
inhibitory activity and infection status [58,59]. Interestingly,
several studies found that the level of PfMSP1-19 specific growth
inhibition correlated poorly with levels of PfMSP1-19 antibodies
measured by ELISA [54–56,59,61]. Importantly, no study has yet
examined the association between MSP1-19 inhibitory antibodies
and prospective risk of symptomatic malaria.
In this study, functional antibodies to MSP1-19 and the
importance of MSP1-19 as a target of acquired immunity were
evaluated. The contribution of MSP1-19 specific antibodies to the
total invasion-inhibitory activity of acquired antibodies was
quantified, and associations between antibodies to MSP1-19 and
protection from parasitization, high grade parasitemia, and
malarial illness were examined in a pediatric treatment-reinfection
study in Papua New Guinea (PNG). Furthermore, differences in
functional activity were evaluated among acquired human
antibodies and antibodies generated in experimental animals by
vaccination with recombinant protein.
Materials and Methods
Study participants and design
Samples were collected during a pediatric treatment-reinfection
study undertaken from June to December 2004 at the Mugil
Elementary School (n=152), Megiar Elementary School (n=44)
and Megiar Primary School (n=10), 50 km North of Madang,
Madang Province, Papua New Guinea [62]. The study was
approved by the Medical Research Advisory Committee (MRAC),
Papua New Guinea Ministry of Health, The Walter and Eliza Hall
Institute Human Research Ethics Committee and the institutional
review board of the Veteran’s Affairs Medical Center (Cleveland,
Ohio). Written consent was obtained from parents/guardians of
all participants. A total of 206 children aged 5 to 14 were enrolled
(median 9.3 years; interquartile range 8.1 to 10.3 years).
Enrolment with peripheral blood and data collection was
conducted over a two-week period in June 2004 by staff from
PNGIMR [62]. After physical examination and baseline bleed, the
children were treated with a 7 day course of artesunate, according
to national guidelines, to clear any current malarial infections.
Over the next 6 months, malaria and parasitemic episodes were
identified with fortnightly follow-ups (active surveillance) and
review by a trained health worker of any child enrolled in the
study who presented with symptoms at the local Mugil Health
Centre (passive surveillance). In cases where symptoms indicated a
current or recent fever, thin and thick blood smears were prepared
to screen for parasite infection and estimation of parasitemia.
Children diagnosed with malaria were treated with sulfadoxine/
pyrimethamine and amodiaquine to cover P. falciparum and P. vivax
according to national guidelines.
Data relating to time to reinfection after treatment, infecting
malaria parasite species as indicated by PCR, parasite density as
indicated by microscopy, red blood cell polymorphisms by PCR,
history of illness as indicated by symptoms and physical
examination were available [62,63]. Some samples were also
collected from PNG adults in the same region, and from residents
of Melbourne, Australia, to act as non-malaria-exposed controls.
Measurement of PfMSP1-19 specific antibodies by ELISA
DNA sequences for P. falciparum MSP1-19 and P. chabaudi
MSP1-19 were ligated into a modified pMal-C2x plasmid (New
England Biolabs) to produce MSP1-19 fusions proteins with a N-
terminal Maltose Binding Protein (MBP) tag. The fusion proteins
were expressed in Escherichia coli BL21(DE3) Origami (Novagen,
Madison, WI, U.S.A.) and purified via nickel-nitrilotriacetic acid
chromatography under native conditions (Qiagen, Valencia, CA,
U.S.A.) and were refolded as per Dutta et al. [64]. Correct folding
of the PfMSP1-19 fusion protein was verified by western blot
analysis with the reduction sensitive monoclonal antibody 4H9/19
[65].
Antigens were coated onto ELISA plates (Costar, Cambridge,
MA, U.S.A.) at 1 mg/ml in 100 ml PBS and incubated overnight at
4uC [21,22,66]. Plates were washed 3 times in PBS with 0.05%
Tween-20 (0.05% PBS-T, Sigma Aldrich, St Louis, MO, U.S.A.)
at room temperature (RT) and blocked with 200 ml 10% skim milk
in 0.05% PBS-T for 2 hours at 37uC. The plates were washed 3
times in 0.05% PBS-T then heat inactivated plasma samples
(100 ml volume diluted to 1/500 in PBS with 0.05% sodium azide)
were added and incubated at RT for 2 hours. Plates were washed
3 times in 0.05% PBS-T and 100 ml of HRPO-conjugated Sheep
anti human IgG (Millipore, Boronia, Melbourne, Australia)
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incubated at RT for 1 hour. The plates were washed 3 times in
0.05% PBS-T and 100 ml of ABTS substrate (Sigma Aldrich, St
Louis, MO, U.S.A.) was incubated in each well for 15 minutes at
RT. The reaction was stopped with the addition of 100 mlo f1 %
SDS and read at 405 nm (Tecan Genios, Gro ¨dig, Austria). A
panel of samples from malaria-exposed adults acted as positive
controls to enable comparison of antibody levels between plates
and different dates of experiments. A panel of serum from
Melbourne donors acted as negative controls.
PfMSP1-19 specific IgG concentration was estimated by coating
two-fold serial dilutions (1 mg/ml-0.00781 mg/ml) of purified
human IgG (reagent grade; Sigma-Aldrich, St. Louis MO,
U.S.A) and purified rabbit IgG (reagent grade; Sigma-Aldrich,
St. Louis MO, U.S.A) onto plates; other wells were coated with
recombinant PfMSP1-19. After blocking wells with 10% skim
milk, two-fold serial dilutions of Mugil children’s plasma (1/1000–
1/32000) or rabbit sera against MSP1-19 (1/4000–1/256000)
were added to separate wells coated with 1 mg/ml PfMSP1-19.
PBS was added to wells coated with human and rabbit IgG. After
incubation for 2 hours, wells were washed, then incubated with
either anti-human or anti-rabbit IgG secondary antibody, then
washed and processed as described above. The MSP1-19 specific
IgG concentration among children’s plasma, or rabbit antisera,
was estimated by reference to the standard curve of human or
rabbit IgG, respectively. Estimated MSP1-19 specific IgG levels
among human samples were expressed relative to the rabbit
MSP1-19 anti-sera.
Estimating antibody avidity by ELISA
After incubating antigen-coated wells with human plasma or
rabbit anti-MSP1-19 antibodies (as described above), wells were
washed and then incubated with ammonium thiocyanate (Sigma-
Aldrich, St. Louis MO, U.S.A) for 20 minutes at concentrations of
8.64 M, 6.91 M, 5.18 M, 4.32 M, 3.46 M, 2.16 M, 1.728 M,
1.08 M, 0.27 M, 0.135 M, 0.067 M. Wells were then washed and
the assay was completed as described earlier. Primary antibodies
were diluted for human (1/2000, 1/4000) and rabbit (1/20000, 1/
40000) samples to yield OD values in the descending linear section
of the absorbance curves. The ammonium thiocyanate concen-
tration that resulted in a loss of 50% of maximum absorbance was
estimated by fitting a line of best fit.
Sample dialysis
Heat inactivated plasma samples (45 minutes at 56uC) were
dialysed as described [67,68]. Briefly, 200 ml of sample was added
to 50 kDa cut-off Tube-O-Dialyzer dialysis tubes (Chemicon
International, Temecula, CA, U.S.A) and the tubes were placed
upside down in PBS so the dialysis membrane contacted the PBS.
Samples were left to dialyse for 2 hours at 4uC and then the PBS
was replaced for further dialysis overnight. Samples were
centrifuged to the bottom of the dialysis tubes and transferred to
100 kDa cut-off Nanosep spin tubes (Pall Life Sciences, Ann
Arbor, MI, U.S.A.) and centrifuged at 13000(G) for 30 minutes at
4uC. Sterile PBS (200 ml) was added and the spin tube centrifuged
at 13000(G) at 4uC. PBS was added to bring the samples back to
the original sample volume (200 ml) and stored at 270uC.
Purification of immunoglobulins by ammonium sulfate
precipitation
Immunoglobulin from twenty pooled Mugil samples with high
levels of PfMSP1-19 specific antibody measured by ELISA
(OD.1.7), 5 plasma samples from PNG adults and serum from
non-exposed Melbourne donors were purified using ammonium
sulfate precipitation [67,68]. Briefly, 300 ml of plasma was diluted
1:5 in normal saline. Saturated ammonium sulfate (Sigma Aldrich,
St Louis, MO, U.S.A., approximately 1 kg/L in water, auto-
claved) was added drop wise to make up 40% of the total volume
and then incubated on ice for 30 minutes. The solution was spun
at 13000(G) for 15 minutes at 4uC before removal of the
supernatant. The pellet was washed in 50% ammonium sulfate
solution in water before pelleting and removal of the supernatant a
second time. The pellet was resuspended in 400 ml of RPMI-
HEPES and the resulting solution was dialysed according to the
preceding method. Immunoglobulin was resuspended off the spin
column in half the original sample volume to concentrate the
sample to approximately twice the initial immunoglobulin
concentration.
PfMSP1-19 specific growth inhibition assays
The PcMEGF (containing PcMSP1-19) and PfM39 (containing
PfMSP1-19) lines [27,54] as well as the PcPHG and PfPHG GFP
fluorescent MSP1-19 transfected lines [69] were used in this study
and will be referred to as simply PcMSP1-19 line or PfMSP1-19
line; all transgenic parasites were generated in isolate D10 (derived
from the PNG isolate FC27). The expression of the PcMSP1-19
and PfMSP1-19 alleles by the transfected parasite lines was
confirmed by Western blot and immunofluorescence assays as
described in O’Donnell et al. 2000 [27]. Parasites were cultured as
described [69,70]. PfMSP1-19 and PcMSP1-19 transfected lines
were maintained on 24 ng/ml pyrimethamine (to select for MSP1-
19 transfectants, Sigma Aldrich, St Louis, MO, U.S.A.) with 5 mg/
ml blasticidin-S-HCl (to select for GFP transfectants, Invitrogen,
Carlsbad, CA, U.S.A.) added when culturing the double
transfected fluorescent lines. One to two cycles prior to assay
setup, and during the assay, drugs were excluded from cultures.
The protocol for measurement of antibody inhibition of parasite
growth used in this study is modified from Persson et al. [67] and is
described and validated in detail elsewhere [69]. Parasites were
cultured for one or two cycles of asexual replication. Mid to late
trophozoite stage cultures (30–40 hours) were washed in fresh
culture medium (37uC) and pelleted by centrifugation then diluted
out to 0.5% to 1% parasitemia at 1% hematocrit for a 1 cycle
assay or 0.1% to 0.3% parasitemia at 1% hematocrit for a 2 cycle
assay. Fresh culture medium and fresh RBCs from 2 different
donors warmed to 37uC were used during assay set-up. Parasitised
RBCs at the appropriate parasitemia, at a volume of 25 mlo r
50 ml, were added to a 96 well U-bottom plate (Falcon, Becton-
Dickinson, Franklin Lakes, NJ, U.S.A) with 2.5 mlt o5 mlo f
sample (for 25 mlt o5 0ml assays respectively) added to give a 1 in
10 dilution of sample. All samples were run in duplicate and in
most cases in repeat experiments. A panel of non-immune serum
from Melbourne donors (provided by the Australian Red Cross)
were included as non-inhibitory controls. The 96 well plates were
placed in a humidified air tight culture box and left at 37uCi n1 %
O2,4 %C O 2 and 95% N2.
One cycle assays with measurement of parasitemia at ring-stage
by microscopy and flow cytometry were cultured for approxi-
mately 24 hours until young to mid rings were present and no
schizont stage parasites remained. For assessment of parasitemia
by microscopy, thin smears of the cell pellets were methanol fixed
and stained with 5% Giemsa (Merck, Darmstadt, Germany).
Slides were blinded and one thousand RBCs were counted for
each slide. Only early to late rings (0 to 20 hours old) were counted
as parasitised RBCs, with each infected RBC counted as a single
parasitized RBC regardless of how many parasites were in the cell.
Due to the variability inherent in microscopy based counts of
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were reviewed by a second person and when duplicate wells
differed by .25% slides were recounted while still blinded. Where
slides were recounted, all four counts were used to calculate
parasitemia.
One cycle assays with measurement of parasitemia at the
pigmented trophozoite stage were cultured for 48 hours post set-
up until parasites were between 30–40 hours post invasion when
they were prepared for flow cytometric analysis as appropriate.
Two cycle trophozoite stage assays were supplemented at 48 hours
post set-up (parasites 30–40 hours post invasion) with the addition
of 5 mlt o1 0ml (25 mlo r5 0ml assay respectively) of fresh culture
medium warmed to 37uC. Forty-eight (1 cycle assay) or 96 (2 cycle
assay) hours post assay set-up, trophozoite stage assays were
prepared for flow cytometry analysis as appropriate. For non-
fluorescent parasite lines, RBCs were resuspended in 100 mlo f
PBS with 10 mg/ml ethidium bromide (EtBr, Bio-Rad, Hercules,
CA U.S.A.), then stained for 1 hour before centrifugation, removal
of the supernatant and resuspension in 200 ml of PBS. GFP
fluorescent parasite lines were resuspended in PBS to make a final
volume of 200 ml. Parasitemia was measured on a Becton
Dickinson FACSCalibur (Franklin Lakes, NJ, U.S.A) flow
cytometer with a 96 well plate sampler attached using Fl-2
(excitation wavelength 488 nm) for EtBr stained parasites and Fl-1
(excitation wavelength 488 nm) for GFP parasites. Typically,
50,000 to 80,000 RBCs were counted for each well. Samples were
analysed using FlowJo software (Tree Star Inc, Ashland, OR,
U.S.A).
PfMSP1-19 growth inhibitory activity measured in this assay
may include both invasion inhibition and intraerythrocytic
parasite growth inhibition. Although PfMSP1-19 specific inhibi-
tory antibodies could be acting through either or both mecha-
nisms, the two mechanisms are not differentiated in this study. For
both the PcMSP1-19 and PfMSP1-19 transfected lines, parasite
growth (G) was determined by dividing the mean parasitemia of
duplicate wells for a test sample (Smean) by the mean parasitemia of
2 or more wells of non-inhibitory control (Cmean, typically
Melbourne control serum) and multiplying by 100 (G={Smean/
Cmea}*100). PfMSP1-19 specific inhibitory activity (InhPf)o fa n
individual sample was then determined by subtracting growth of
the PfMSP1-19 test line (Gpf) from growth of the PcMSP1-19
control line (Gpc) for each sample tested (InhPf=G pc-Gpf). Rabbit
antibodies to confirm MSP1-19 specific inhibition were raised
against C-terminal fragments of P. falciparum and P. chabaudi
MSP1-19 in an earlier study [54].
Variation in the assay was estimated as (+/2) 2 standard
deviations around the mean of the Melbourne control sera used in
assays. The level of potential PfMSP1-19 specific inhibition for
Melbourne control samples was determined by subtracting
parasite growth of the PfMSP1-19 line from the growth of the
PcMSP1-19 line for each individual sample. Any difference in
growth can be attributed to assay variation since there was no
MSP1-19 antibodies detected in the Melbourne control sera. Two
standard deviations of MSP1-19 specific inhibition for Melbourne
control sera was determined separately for each set of experimen-
tal conditions and is termed the ‘‘variation threshold’’. Alterna-
tively, the number of samples above arbitrary cutoffs of 10% and
15% are also considered for 2 cycle assays using non-dialysed and
dialysed plasma as has been done in other studies [58,59].
Statistical Analysis
Differences between categorical variables was assessed using
chi-squared or Fisher’s exact test, where appropriate, and
differences in medians were assessed using the Mann-Whitney U
test. Spearman’s correlation was used to determine correlations
between two data sets. These tests were performed with Prism 5.0a
(GraphPad Software Inc, San Diego, CA, U.S.A.). To determine
the association between antibody levels and risk of P. falciparum
infection and symptomatic malaria, ELISA data were stratified
into 3 equal groups (tertiles) reflecting low, medium and high
responders according to OD values for each antigen. GIA data
was categorised into (#0%, ,5%, 5–9.99% and $10%
inhibition). Kaplan-Meier curves were generated for time-to-event
(infection or clinical episode) data and compared using a log-rank
test. Cox proportional hazards models were used to calculate
hazard ratios for the association of antibody variables with risk of
high density P. falciparum parasitemia and symptomatic P. falciparum
malaria. Assumptions of proportional hazards were assessed
graphically and for antibody variables that showed non-propor-
tional hazards, results from Cox regression including the antibody
variable and antibody variable by time interaction are reported
[21,22]. Hazard ratios reported are unadjusted or adjusted for the
predefined covariates of age (binary variable: ,9 years, $9 years)
and location of residence [21,22,62]. Data analysis was performed
using STATA 9.2 statistical analysis software (STATA Corpora-
tion, College Station, TX, U.S.A.).
Results
Acquisition of P. falciparum MSP1-19 specific antibodies
in plasma by ELISA
Previously we have described the presence of antibodies to
recombinant PfMSP1-19 (his-tagged, expressed in E. coli) in this
cohort [43]. In the present study, antibodies to recombinant
MSP1-19 from P. falciparum as well as P. chabaudi were measured.
Comparison between IgG levels to the PcMSP1-19 and PfMSP1-
19 antigens allowed the measurement of antibodies specific to
PfMSP1-19, accounting for cross-reactive or non-specific antibod-
ies. PfMSP1-19 specific antibodies were calculated by deducting
the reactivity to PcMSP1-19 from the reactivity to PfMSP1-19 for
each sample. Quantifying the relative levels of antibodies to P.
falciparum and P. chabaudi MSP1-19 was also important to interpret
results from growth inhibition assays using the MSP1-19
transgenic parasites, which are described later.
Plasma antibodies were measured by ELISA to recombinant
MSP1-19 from P. falciparum and P. chabaudi among the 206
baseline samples of the Mugil cohort. The median OD of the 206
Mugil children’s samples for the PcMSP-19 antigen was 21-fold
lower than for the PfMSP1-19 antigen (Fig. 1A) and the majority
of samples showed little reactivity to the PcMSP1-19 antigen,
regardless of the reactivity to the PfMSP1-19 antigen (Fig. 1B). Of
the 206 samples, 192 (93.2%) were positive (defined as OD.mean
+3 standard deviations of 9 non-malaria exposed Melbourne
control serum) for PfMSP1-19 specific IgG. The prevalence of
PfMSP1-19 antibodies was associated with age, with a significantly
greater proportion of children older than 9 years (97.4%) having
PfMSP1-19 IgG than children 9 years of age or less (87.9%,
P=0.007). Children greater than 9 years also had a significantly
higher median OD (1.28 [0.65–1.72]) than children 9 years of age
or less (0.96 [0.17–1.62], P=0.006). A significantly higher
proportion of children with concurrent parasitemia at the time
of sampling had PfMSP1-19 specific IgG (98.6%) than those who
were PCR negative (82.1%, P,0.0001), and the median OD of
parasitemic children (1.26 [0.57–1.69]) was also significantly
higher than that of PCR negative children (0.99 [0.13–1.46],
P=0.01). The associations between age or infection status and
prevalence or levels of PfMSP1-19 IgG measured by ELISA were
found to be largely due to the lower IgG levels in children that
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(Fig. 1C and 1D).
PfMSP1-19 is not a major target of growth-inhibitory
antibodies
Plasma samples, with and without dialysis, were tested in
growth inhibition assays conducted over 2 cycles of parasite
replication, which have been previously optimized and validated
[67,69]. Final parasitemia was measured by flow cytometry,
which has a greater reproducibility than microscopy [67,69].
Samples from 192 of the 206 children were first tested in single or
duplicate experiments without prior dialysis (Fig. 2A). Results for
14 samples were excluded because of technical reasons.
Comparison of median growth for the PcMSP1-19 line
(expressing the C-terminal 19 kDa fragment from the rodent
malaria P. chabaudi) and the PfMSP1-19 line (expressing the wild-
type C-terminal 19 kDa fragment from P. falciparum D10) for all
samples showed potentially specific inhibition of the PfMSP1-19
line of 7.1% (PcMSP1-19 median growth 61.7%, PfMSP1-19
median growth 54.6%; n=192, P,0.0001; range 212.7% to
24.9%, Fig. 2B). There was evidence of PfMSP1-19 specific
inhibition (i.e. growth of the PfMSP1-19 line,growth of the
PcMSP1-19 line) for 61 samples when using a cut-off of .10%
difference in inhibition of the two lines, and for 20 samples when
using a cut-off of .15% difference. By comparison, potential
PcMSP1-19 specific inhibition (i.e. growth of the PcMSP1-19
line,growth of the PfMSP1-19 line) was seen with only 3 samples
when using a cut-off of .10% We further examined the
significance of MSP1-19 as a target of inhibitory antibodies
among those samples that demonstrated the highest levels of total
growth inhibition. When examining the top third of samples with
the highest level of total growth inhibition, the median PfMSP1-
19 specific inhibition for these samples was only 4.1% suggesting
that MSP1-19 is not a major target of acquired inhibitory
antibodies. Measurement of parasite growth was highly repro-
ducible when compared between duplicate experiments (n=85,
Table 1, Fig. 3A) with very few samples showing PfMSP1-19
specific inhibition (Fig. 3B).
Samples were dialysed to remove anti-malarial drugs and non-
specific malarial inhibitors [67] and tested in 2 cycle flow-
cytometry based assays (n=205; one sample was not dialysed due
to limited volume, Fig. 2A). All dialysed plasma samples (n=205)
were tested in duplicate in two separate assays for both the
PcMSP1-19 and PfMSP1-19 lines. Comparison between the
median parasite growth for duplicate experiments of the PcPHG
and PfPHG transfected lines indicated little or no difference in the
inhibition of the two lines (Fig. 2C); only 0.1% of the growth
inhibitory activity could be classified as PfMSP1-19 specific
(median growth of PcMSP1-19 63.8%, PfMSP1-19 63.7%;
n=205, P=0.2, range 222.8% to 17.4%). There was evidence
of PfMSP1-19 specific inhibition for 10 samples when using a cut-
off of .10% difference in inhibition of the two lines, and for only 2
samples when using a cut-off of .15% difference. By comparison,
potential PcMSP1-19 specific was seen with 7 samples when using
a cut-off of .10%, and one sample when using a cut-off of .15%
difference. There was a high level of reproducibility between
duplicate experiments (Table 1, Fig. 3C). Total parasite growth
inhibition was evident for a proportion of dialysed samples;
however, these inhibitory samples did not show evidence of
PfMSP1-19 specific inhibition (Fig. 3D). When examining the
third of samples with the highest level of total growth inhibition,
the median PfMSP1-19 specific inhibition for these samples was
1.8%, further suggesting that MSP1-19 is not a major target of
acquired inhibitory antibodies.
Figure 1. MSP1-19 IgG levels measured by ELISA and associations with age and parasitemic status at baseline bleed. (A) IgG reactivity
against recombinant PcMSP1-19 and PfMSP1-19 for 206 Mugil plasma samples as measured by ELISA. (B) Correlation between levels of PcMSP1-19
and PfMSP1-19 IgG reactivity measured by ELISA for individual Mugil plasma. Levels of PfMSP1-19 specific IgG (PfMSP1-19 absorbance at 405 nm
minus PcMSP1-19 absorbance at 405 nm) for children ,9 years or $9 years of age (Median 9.3 years, 41% of children ,9 years) at the baseline bleed
separated based on (C) P. falciparum negative (n=67) or (D) P. falciparum positive (n=139) infection status identified by PCR at the baseline bleed.
For A, C, and D, the bar and box represent median and IQR and whiskers represent the 5
th and 95
th percentiles.
doi:10.1371/journal.pone.0027705.g001
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antibodies by ELISA were pooled and IgG was purified using
ammonium sulfate precipitation, allowing concentration of
immunoglobulin and removal of non-specific inhibitors (Fig. 2A).
Plasma from 5 PNG adults with high levels of PfMSP1-19 IgG by
ELISA were treated by ammonium sulfate precipitation to purify
Figure 2. PfMSP1-19 inhibition by Mugil plasma under various experimental conditions. (A) Level of PfMSP1-19 specific inhibition
measured by flow cytometry for non-dialysed Mugil plasma (6, n=192, 2 cycle), dialysed Mugil plasma (+, n=205, 2 cycle), ammonium sulfate
precipitated PNG plasma at a 1 in 10 dilution (¤, n=6, 2 cycle), ammonium sulfate precipitated PNG plasma at a 1 in 5 dilution (w, n=6, 2 cycle), non-
dialysed Mugil plasma (m, n=33, 1 cycle) and non-dialysed Mugil plasma measured by microscopy (N, n=25, 1 cycle). Central bar (green) represents
the median MSP1-19 specific inhibition for the plasma samples. Boxes (blue) represent 2 standard deviations of the mean MSP1-19 specific inhibition
of Melbourne control samples as a measure of assay variability. Bars (red) represent the maximum and minimum values of MSP1-19 specific inhibition
for Melbourne controls. PfMSP1-19 specific inhibition was defined as the growth of PcMSP1-19 line minus growth of PfMSP1-19 line, expressed as a
percentage of non-inhibitory controls. Samples were tested in duplicate and correlations between duplicate experiments are outlined in Table 1.
Median growth of the PcMSP1-19 line and PfMSP1-19 line in the presence of (B) non-dialysed Mugil plasma (n=192) and (C) dialysed Mugil plasma
(n=205) in 2 cycle flow cytometry based assays. Error bars represent inter-quartile range with dots representing samples with inhibition that falls
outside this range. Horizontal bar and box represent median and IQR, whiskers represent the 5
th and 95
th percentiles.
doi:10.1371/journal.pone.0027705.g002
Table 1. Reproducibility of parasite growth measurements between repeat experiments.
Cycle Method Plasma Line rs n P Line rs nP
2 FN DPc 0.88 85 ,0.0001 Pf 0.8 85 ,0.0001
2 FD Pc 0.93 205 ,0.0001 Pf 0.9 204 ,0.0001
1 FN DPc 0.75 25 ,0.0001 Pf 0.76 25 ,0.0001
1 MN DPc 0.71 25 ,0.0001 Pf 0.48 25 =0.0153
F=flow cytometry, M=microscopy.
ND=non-dialysed plasma, D=dialysed plasma.
Pc=P. chabaudi MSP1-19 line; Pf=P. falciparum MSP1-19 line.
rs=spearmans correlation coefficient.
n=number of samples compared between 2 experiments.
P=significance of correlation.
doi:10.1371/journal.pone.0027705.t001
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PfMSP1-19 specific inhibitory activity was detected for the
purified IgG at a 1 in 10 dilution (median growth was 75.2% for
PcMSP1-19 and 74.6% for PfMSP1-19; n=6; range 24% to
0.7%) or using a 1 in 5 dilution (median growth was 93.1% for
PcMSP1-19 and 86.9% for PfMSP1-19; n=6; range 27% to
13%). The difference between growth of the PcMSP1-19 and
PfMSP1-19 parasite lines for the ammonium sulfate precipitated
children’s pooled plasma was 0.6% at a 1 in 10 dilution and 6.2%
at a 1 in 5 dilution.
Figure 3. Reproducibility of PfMSP1-19 specific growth inhibition assays and levels of PfMSP1-19 specific inhibition for
representative samples. (A) Correlation of PfMSP1-19 line growth between duplicate experiments for 85 samples of the non-dialysed Mugil
plasma samples showing a high level of assay reproducibility (rs=0.88, n=85, P,0.0001). (B) Subset of non-dialysed Mugil plasma samples showing
total growth inhibitory activity but little or no PfMSP1-19 specific inhibitory activity in 2 cycle assays. Confirmation that the assay was able to measure
PfMSP1-19 specific inhibition was provided through the use of inhibitory rabbit antisera raised against PfMSP1-19 (anti-Pf). (C) Correlation of PfMSP1-
19 line growth between duplicate experiments for dialysed Mugil plasma samples showing a high level of assay reproducibility (rs=0.93, n=204,
P,0.0001). (D) Subset of dialysed Mugil plasma showing total growth inhibitory activity but little or no PfMSP1-19 specific inhibitory activity in 2
cycle assays. Correlation between parasite growth measured in flow cytometry or microscopy based 1 cycle assays for (E) the PcMSP1-19 line
(rs=0.72, n=25, P,0.0001) and (F) the PfMSP1-19 line (rs=0.59, n=25, P=0.0018) highlight comparable levels of growth between the two methods.
Parasite growth was expressed as a percentage of the mean growth of a panel of non-dialysed or dialysed Melbourne control sera included on each
assay plate.
doi:10.1371/journal.pone.0027705.g003
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not a major component of the in vitro growth inhibitory activity of
children’s plasma samples, and that there was little specific
inhibition observed for the few adult samples tested. Importantly,
PfMSP1-19 and PcMSP1-19 specific rabbit anti-sera tested in
parallel in all assays consistently inhibited the growth of the
respective lines, indicating that MSP1-19 specific inhibition could
be effectively measured in these experiments (Fig. 3B and 3D).
Further evaluation of MSP1-19 specific inhibitory
antibodies by microscopy and flow cytometry
To further test for the presence of PfMSP1-19 specific inhibitory
antibodies, one-cycle assays were performed to enable comparison
with earlier published studies, which generally tested inhibition
over one cycle only. Similar to findings with two-cycle assays, there
was very little difference between the median growth of the
PcMSP1-19 and PfMSP1-19 parasite lines in the presence of non-
dialysed plasma samples (Fig. 2A); results suggest total PfMSP1-19
specific inhibition of only 1.1% (median growth of PcMSP1-19
75.2%, and PfMSP1-19 74.1%; n=33, P=0.9, range 215.1% to
11.3%). There was a high level of reproducibility between
experiments (Table 1).
Since most previous studies that have measured PfMSP1-19
specific inhibitory antibodies have used microscopy to measure
parasite growth, it was possible that the use of flow cytometry in
the current study may have explained the failure to detect growth
inhibition effectively. Therefore, 25 plasma samples were tested for
PfMSP1-19 specific inhibitory activity and growth was measured
by microscopy in parallel with flow cytometry. Microscopy slides
were blinded by a third person for all experiments and then read
by one of the authors. Counts for 2 separate microscopy
experiments were available for all 25 samples with a strong
correlation evident for repeat experiments (Fig. 2A, Table 1). In
these assays there was little evidence of PfMSP1-19 specific growth
inhibition (1.3% overall) for Mugil samples tested in a 1 cycle
microscopy assay (median growth for PcMSP1-19 69.5% and
PfMSP1-19 68.2%; n=25, P=0.5, range 227.9% to 11.6%).
There was a strong correlation for measurements of PcMSP1-19
line (rs=0.72, n=25, P,0.0001, Fig. 3E) and PfMSP1-19 line
(rs=0.59, n=25, P=0.0018, Fig. 3F) growth between flow
cytometry and microscopy based counts for the 25 Mugil plasma
samples available for comparison in 1 cycle assays.
Taken together, these data suggest that the detection of
PfMSP1-19 specific growth inhibitory activity was not enhanced
by the use of one-cycle assays or microscopy, and confirmed
findings of earlier experiments that PfMSP1-19 specific antibodies
were not a major component of the in vitro growth inhibitory
activity of children’s plasma. PfMSP1-19 and PcMSP1-19 specific
rabbit anti-sera inhibited growth of the target lines consistently,
indicating that failure to detect MSP1-19 specific growth
inhibitory activity in the Mugil plasma was not attributable to
problems with the assay.
Associations between acquired antibodies to PfMSP1-19
and protection from malaria and reinfection
To investigate the association between PfMSP1-19 specific IgG
levels by ELISA and protection against malaria or infection,
children were defined as low, medium or high responders to the
PfMSP1-19 antigen (based on tertiles). Levels of response were
then related to four P. falciparum outcomes: symptomatic P.
falciparum malaria (defined as fever plus Pf.5000/ml); high density
parasitemia (Pf.5000/ml); moderate density parasitemia (Pf.
500/ml) and reinfection (detected by both light microscopy and
PCR). Specific IgG to PfMSP1-19 was defined as the reactivity to
recombinant PfMSP1-19 minus the reactivity to recombinant
PcMSP1-19 for each sample. There was strong evidence of a
protective effect of high levels of anti-PfMSP1-19 specific
antibodies measured by ELISA (IgG reactivity to PfMSP1-19
minus IgG reactivity to PcMSP1-19) with protection against high
density parasitemia and symptomatic P. falciparum infection. High
levels were associated with reduced risk of high density infection
(P=0.0007; Hazard ratio [HR]=0.40; adjusted HR=0.48) and
symptomatic P. falciparum infection (P=0.0004; HR=0.35;
aHR=0.43), Fig. 4B, Table 2). There was no evidence of an
association between P. chabaudi MSP1-19 specific responses and
high density parasitemia and symptomatic P. falciparum infection.
In comparison to other antibody associations evaluated in this
cohort, the strength of the protective association for PfMSP1-19-
specific antibodies was similar to AMA1 (aHR, 0.34), but not as
strong as found for antibodies to some EBA and PfRh antigens
(Eg. aHR for PfRh2_2030 was 0.2; aHR for EBA175 region III–V
was 0.27 [21,22]. As reported previously for IgG MSP1-19 [43],
and for other antigens [21][22], there was no association between
low, medium or high levels of PfMSP1-19 specific IgG and time to
P. falciparum reinfection per se (P=0.81 and P=0.91, for light
microscopy and PCR respectively, Fig. 4A); there was some
evidence of an association between high levels of PfMSP1-19 IgG
and reduced time to moderate density P. falciparum (.500/ml,
P=0.028).
In order to assess the association of growth inhibitory antibodies
with protection against clinical malaria, MSP1-19 P. falciparum-
specific growth inhibition data from testing both dialysed and non-
dialysed samples was used. Although there was a strong association
between antibodies to PfMSP1-19 measured by ELISA and
protective immunity, there was no evidence that PfMSP1-19
specific inhibitory antibodies were associated with protection from
malaria. Individuals with potentially significant levels of PfMSP1-
19 specific inhibition (.10%) using dialysed plasma had an
increased risk of symptomatic and high density parasitemia
compared to those with no inhibition (Table 2). However, since
there was little evidence of PfMSP1-19 specific growth inhibition
in samples from the cohort, evaluating associations between
growth inhibition and protection from malaria are problematic.
There was no association of PfMSP1-19 specific growth inhibition
and risk of symptomatic malaria for non-dialysed samples
(Table 2).
Concentration and avidity of PfMSP1-19 antibodies
estimated by ELISA
To assess whether the lack of MSP1-19 specific growth
inhibitory activity could be attributed to low PfMSP1-19 antibody
concentration in children’s samples or low antibody avidity or
affinity, PfMSP1-19 IgG levels and avidity were compared
between growth inhibitory rabbit antisera and a subset of
children’s plasma samples; a selection of plasma samples with
high reactivity to MSP1-19 by ELISA was used. PfMSP1-19
specific antibody levels in growth inhibitory rabbit antisera that
was generated by immunization was estimated to be 12.5-fold
higher than that of the panel of highly reactive Mugil plasma
samples (n=6, Fig. 5A). The rabbit antisera routinely caused
around 70% growth inhibition at 1/10 dilution in 2-cycle assays
(Fig. 3B), with dilution to 1/80 resulting in a loss of PfMSP1-19
specific growth inhibitory activity (data not shown). At a 1 in 80
dilution, the concentration of PfMSP1-19 specific IgG in rabbit
antisera would still be approximately 1.5 fold higher than the
median concentration for the children’s plasma samples tested.
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recombinant PfMSP1-19 was estimated using serial dilutions of
ammonium thiocyanate, added to wells after first allowing
antibodies to bind immobilized antigen. The concentration of
ammonium thiocyanate that reduced OD by 50%, compared to
control(noammoniumthiocyanateadded)wasused asa measureto
compare avidity between samples. The concentration required for a
50% reduction for the rabbit antisera (4.4 M) was comparable to
that observed for a panel of Mugil plasma samples (median 4.7 M,
range 3.6 M to 5.8 M, n=6, Fig. 5B). We also calculated the
relative reduction in antibody binding by thiocyanate treatment
among samples. At 4.3 M, ammonium thiocyanate reduced
antibody binding among children’s by 49.5% (median; range
29.8–82%) and by 50.5% for the rabbit antisera (all sera tested at 1/
2000 dilution). Together, these data suggest that the lack of MSP1-
19 specific growth-inhibitory activity of children’s plasma samples
compared to rabbit antisera could be explained by a lower
concentration of specific antibodies among children’s plasma
samples, and not by lower avidity of antibody binding.
Discussion
MSP1-19 is an important antigenic region of the larger 42 kDa
fragment of MSP1, which has long been considered a promising P.
falciparum vaccine candidate. Several ELISA based studies have
reported significant associations between levels of antibodies to
MSP1-19 and protection from malaria [38,40–42,71–74]; a recent
meta-analysis indicated a 19% reduction in malaria risk for
individuals with MSP1-19 antibodies [20]. Functional growth
inhibitory MSP1-19 specific antibodies have also been reported in
samples from malaria exposed individuals using in vitro assays [54–
61]. To date, no study has reported associations between PfMSP1-
19 specific growth inhibitory activity and protection from
symptomatic malaria, or quantified the importance of MSP1-19
as a target of the overall growth-inhibitory activity of acquired
human antibodies. Here we report that although IgG to MSP1-19
measured by ELISA is associated with protection from malaria,
MSP1-19 is not a significant target of growth-inhibitory antibodies
in this cohort.
Of the 206 Mugil plasma samples collected at baseline, 95.6%
were found to be PfMSP1-19 IgG positive by ELISA, suggesting
the majority of children had had significant prior exposure to P.
falciparum MSP1-19 antigen, consistent with the high rate of P.
falciparum reinfections (96% measured by PCR) observed in the
study [62]. Older children, and children that were PCR positive
for P. falciparum infection at baseline, were found to have higher
levels of PfMSP1-19 antibodies measured by ELISA than younger
Figure 4. PfMSP1-19 specific IgG levels measured by ELISA and association with protection from malaria or re-infection. (A) Kaplan-
Meier curve showing the association between PfMSP1-19 specific (PfMSP1-19 minus PcMSP1-19) IgG by ELISA and time to reinfection detected by
PCR for low (blue), medium (red) and high (green) responders. (B) Kaplan-Meier curve showing the association between low, medium and high levels
of PfMSP1-19 specific IgG and risk symptomatic malarial episode (fever+Pf.5000/ml).
doi:10.1371/journal.pone.0027705.g004
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that levels of PfMSP1-19 specific antibodies measured by ELISA
are associated with recent and cumulative exposure to P. falciparum
as expected.
Analysis of the association between PfMSP1-19 antibody levels
measured by ELISA and first P. falciparum malaria episode post
drug treatment indicated that high levels of PfMSP1-19 specific
(PfMSP1-19 OD minus PcMSP1-19 OD) antibodies were associ-
ated with reduced risk of symptomatic malaria, which remained
significant after adjusting for differences in age and location of
residence. Time to first moderate or high density P. falciparum
infection was significantly increased in children with high PfMSP1-
19 antibody levels, which is consistent with the current
understanding of acquired immunity and proposed mechanisms
Table 2. Cox regression analysis of the association of MSP1-19 responses with symptomatic and high density parasitemia.
Fever+Pf.5000
HR
1 [95%CI] P aHR
2 [95%CI] P
Pf - Pc ELISA
MSP1-19 (L)
3 11
MSP1-19 (M) 0.45 0.26 0.78 0.005 0.56 0.31 1.00 0.052
MSP1-19 (H) 0.35 0.19 0.64 0.001 0.43 0.23 0.80 0.008
Pc ELISA
MSP1-19 (L) 1 1
MSP1-19 (M) 1.09 0.48 2.48 0.832 1.14 0.50 2.59 0.762
MSP1-19 (H) 0.58 0.23 1.50 0.262 0.64 0.25 1.66 0.358
GIA dialysed
MSP1-19 (0%)
4 11
MSP1-19 (,5%) 1.85 0.98 3.52 0.059 1.72 0.90 3.29 0.104
MSP1-19 (5–9.9%) 2.68 1.37 5.24 0.004 2.71 1.33 5.52 0.006
MSP1-19 (.10%) 10.41 4.36 24.84 ,0.001 8.20 3.34 20.11 ,0.001
GIA non-dialysed
MSP1-19 (0%) 1 1
MSP1-19 (,5%) 0.67 0.16 2.81 0.584 0.89 0.21 3.77 0.869
MSP1-19 (5–9.9%) 0.88 0.23 3.32 0.852 1.03 0.27 3.96 0.967
MSP1-19 (.10%) 1.66 0.48 5.79 0.424 1.90 0.53 6.81 0.323
1HR – hazard ratio for risk of malaria (fever+P. falciparum parasitemia .5000 parasites per microlitre of blood).
2aHR – adjusted hazard ratios (adjusted for age and location of residence).
3High (H), medium (M), and low (L) antibody levels were defined by tertiles.
4Level of MSP1-19 specific inhibition is indicated in brackets.
doi:10.1371/journal.pone.0027705.t002
Figure 5. PfMSP1-19 antibody concentration and avidity of binding in Mugil plasma and rabbit sera. (A) Comparison of PfMSP1-19
specific antibody levels estimated by ELISA between Mugil plasma and growth inhibitory vaccinated rabbit sera raised against PfMSP1-19 (anti-Pf).
Relative levels are expressed as a proportion of the PfMSP1-19 rabbit antisera. (B) Comparison of IC50 (M) for ammonium thiocyanate inhibition of
PfMSP1-19 antibody binding to recombinant PfMSP1-19 for Mugil plasma and growth inhibitory vaccinated rabbit sera raised against PfMSP1-19. The
6 Mugil plasma samples tested were selected based on having high levels of PfMSP1-19 IgG as measured by ELISA. Bars represent the mean and
range of 2 independent experiments (antibody concentration in Figure A) or the mean and standard deviation of three independent experiments
(thiocyanate concentration in Figure B).
doi:10.1371/journal.pone.0027705.g005
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to a previous study of MSP1-19 antibodies in this cohort [43].
However, in this study we assessed IgG specificity to PfMSP1-19
by deducting reactivity to recombinant MSP1-19 of P. chabaudi in
order to account for non-specific binding, which is a concern that
is often expressed by researchers in the field.
The results of this study support the findings of a number of
other studies which have shown an association between IgG
antibody levels to PfMSP1-19 measured by ELISA and control of
parasitemia or protection from symptomatic P. falciparum malaria
[38,40–42,71–74]. The association between MSP1-19 antibody
levels and protection from disease is evident in both infants and
young children, which suggests that protection associated with
MSP1-19 antibodies develops early in people’s exposure to
malaria [38,40,74]. Combined, these studies suggest that IgG
antibodies to MSP1-19 may be an important component of
immunity to P. falciparum malaria or alternatively may act as a
strong predictive marker of exposure, and hence immunity.
Our comprehensive testing suggests that there is little PfMSP1-
19 specific growth inhibition in plasma samples from the Mugil
cohort, under various experimental conditions. Furthermore, any
potential MSP1-19 specific inhibitory activity was not associated
with protection from malaria or re-infection. The median level of
PfMSP1-19 specific inhibition for non-dialysed Mugil plasma
tested in a 2 cycle assay, dialysed Mugil plasma tested in a 2 cycle
assay, non-dialysed Mugil plasma in a 1 cycle assay measured by
flow cytometry or microscopy, and ammonium sulfate precipitated
IgG at a 1 in 10 or 1 in 5 dilution was generally minimal and lower
than the levels reported in other studies [54–58]. The highest
median PfMSP1-19 specific inhibition was recorded with 2 cycle
assays using non-dialysed samples. However, there were very few
samples with PfMSP1-19 specific inhibition above a commonly
used cut-off of 15% and no samples had levels of PfMSP1-19
specific inhibition approaching the highest levels seen in other
studies, despite the fact that two cycle growth inhibition assays
have been previously reported to have greater sensitivity compared
to 1 cycle assays [67,69,75]. This suggests that the PfMSP1-19
specific inhibition seen for the two cycle non-dialysed samples
might be attributable to assay variation rather than antibody-
mediated growth inhibition. Other antigens have been identified
or proposed as targets of acquired human growth inhibitory
antibodies, including AMA1 [76], erythrocyte binding antigens
[66], and PfRh ligands [66]. These may be important targets of
inhibitory antibodies in this population.
Importantly, rabbit polyclonal antibodies raised against recom-
binant PfMSP1-19 and PcMSP1-19 were used in all assays and
consistently found to specifically inhibited growth of the target
parasite lines. This suggests that antibody mediated MSP1-19
specific inhibition in malaria exposed samples could be measured
if the inhibitory activity of the antibodies was high enough. In this
study, a variability threshold was determined from paired
(PcMSP1-19 line or PfMSP1-19 line) Melbourne control samples
to provide a reliable indicator of the amount of measured MSP1-
19 specific inhibition that could be attributable to assay variability.
In this way it was hoped to establish a more valid cut-off for
defining MSP1-19 positivity or negativity than using an arbitrary
value of 5 to 15% as has been adopted previously [58–60]. Using
this method, notional MSP1-19 specific inhibition detected in the
majority of samples could be explained by assay variability.
It was noticeable that the number of samples displaying
PfMSP1-19 specific inhibition was usually balanced by the number
of samples showing negative PfMSP1-19 specific inhibition (i.e.
PcMSP1-19 specific inhibition), the exception being the two cycle
non-dialysed data. Given the distribution of MSP1-19 specific
inhibition it would appear likely that negative PfMSP1-19 specific
inhibition reflects assay variability rather than a PcMSP1-19-like
inhibitor. It is interesting to note that the maximum and minimum
levels of notional MSP1-19 specific inhibition for Melbourne
control samples lie at similar levels to the maximum and minimum
levels of inhibition seen for the Mugil samples. Again this suggests
that MSP1-19 specific inhibition detected in Mugil samples could
be explained by assay variability. Importantly, the variability seen
in Melbourne control samples was not an indication of poor
reproducibility of flow cytometry based assays, since there was a
high level of reproducibility for measurements of parasite growth
between duplicate wells and between experiments across this
study.
One possible explanation for the lack of PfMSP1-19 specific
growth inhibition seen in this study might be related to the level of
exposure for this cohort compared to others. Previous studies
reported high levels of PfMSP1-19 specific inhibition in samples
collected from children and adults living in highly malaria
endemic areas [54,61] with no correlation between age and
PfMSP1-19 specific growth inhibition identified for one of the
studies [61]. Other studies have reported PfMSP1-19 specific
growth inhibitory activity in samples collected from people with
limited exposure to P. falciparum malaria [55,56]. Therefore, these
studies suggest that previously detected PfMSP1-19 growth
inhibitory antibodies are not confined to samples collected from
areas of high endemicity and from people with high levels of
exposure. The levels and growth inhibitory activity of PfMSP1-19
specific antibodies in plasma samples during the acute phase of
reinfection have not been examined in this study; antibodies were
only measured at enrolment. It is likely that total antibody levels to
PfMSP1-19 would rise in response to reinfection. However, the
minimal levels of PfMSP1-19 specific growth inhibitory activity
seen in the study population, and the lack of any association
between MSP1-19 specific inhibitory antibodies and active
parasitemia at enrolment, suggests that subsequent parasite
reinfection is unlikely to increase PfMSP1-19 inhibitory activity.
Estimation of PfMSP-19 IgG concentration in rabbit antisera
and Mugil plasma with high levels of PfMSP1-19 antibodies
suggested that antibody concentration may be an important factor
limiting ability to detect PfMSP1-19 specific inhibition using this
assay. PfMSP1-19 specific IgG was 12.5 fold higher in rabbit
antisera than in a panel of Mugil plasma. When the rabbit antisera
were diluted down such that the concentration of IgG was similar
to that seen in the Mugil plasma, there was loss of growth
inhibitory activity. This suggests that levels of PfMSP1-19
antibodies in Mugil samples may not be high enough to allow
detection of MSP1-19 specific growth inhibition in this assay. The
avidity of PfMSP1-19 specific binding to the recombinant
PfMSP1-19 antigen appeared comparable in rabbit antisera and
Mugil plasma, suggesting that differences in antibody avidity or
affinity did not contribute to the reduced PfMSP1-19 specific
inhibition by Mugil plasma compared to rabbit antisera. However,
these results should be interpreted with caution since using
ammonium thiocyanate elution in ELISA provides an estimate of
the relative avidity of antibodies in vitro, but may not faithfully
represent avidity or affinity in vivo. Additionally, differences in the
fine specificity of antibodies may also contribute to differences
observed in the inhibitory activity of human and rabbit antibodies.
The limited PfMSP1-19 growth inhibitory activity detected in
this study differs markedly to earlier published studies reporting
greater levels of MSP1-19 specific inhibition in serum or plasma
(Table S1) [54,55,61]. One possible explanation noted by
Murhandarwati et al. (2009) [59], is that several earlier studies
used the pyrimethamine sensitive D10 wildtype line as the test line
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[54,55,61]. In this and other recent studies [56–60], the
pyrimethamine resistant PfM39 (also the PfPHG line this study)
PfMSP1-19 transfected line was used together with the PcMEGF
or PyMEGF (also the PcPHG line this study) comparison line,
ensuring that any residual pyrimethamine in plasma samples
should not contribute to differential growth between the lines.
More recent studies [59,60], including this study, have also moved
towards using flow cytometry based counts of parasitemia which
has reduced variability and improved reproducibility compared to
microscopy based measurements [67,69,75]. It is possible that
microscopy-based assays are able to measure growth differences
between the Pf and Pc lines that are not detected by flow
cytometry, but our comparison of the two assays have suggested
that they give similar results.
In conclusion, although MSP1-19 IgG levels measured by
ELISA were associated with protection, there was little or no
PfMSP1-19 specific growth inhibitory activity measurable in the
Mugil cohort, probably because antibodies were not of a high
enough concentration. This suggests that the association between
MSP1-19 IgG levels measured by ELISA and protection from
disease may be a marker of protective immunity rather than being
directly involved in protective mechanisms, or may indicate that
MSP1-19 antibodies contribute to protection by mechanisms other
than growth inhibition. Studies in a humanized mouse model
suggest that antibodies to MSP1-19 can protect against parasit-
emia through an interaction dependent on Fc Receptors and
phagocytic cells, rather than inhibition of invasion [52]. In
conclusion, the findings presented here contribute to our
understanding of human immunity to malaria, particularly the
targets and mechanisms of immunity, and will be valuable for
informing vaccine development of MSP1 and other antigens.
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Table S1 Summary of PfMSP1-19 specific inhibition levels
reported in different studies.
a S=serum. P=plasma.
b M=microscopy based assay. F=flow cytometry based assay.
H=Hypoxanthine uptake assay.
c Microscopy based assays for Bagabag Island and Madang
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xanthine uptake based assays for Bagabag Island and Madang
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[54].
d Interpretation from Figures 2C and 2D and information in
text.
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have significant PfMSP1-19 specific inhibition. Data for
remaining 11 travelers not reported.
f Interpretation from Figures 2B and 3. Spaghetti plots of
timepoints for all samples available in supplementary file 4 of
the manuscript.
g Calculated median for all 137 samples listed in table 1 of the
manuscript. Calculated medians for the 3 timepoints are t=0
(9%, n=65), t=1 (10%, n=37), t=28 (214%, n=35).
NR=not reported in manuscript.
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